Cancer Center Support Grant P30

项目摘要/摘要 加州大学戴维斯分校综合癌症中心(UCDCCC)，与劳伦斯·利弗莫尔国家大学联合成立的财团 实验室(LLNL)是加州大学戴维斯分校健康系统和加州大学戴维斯分校支持下的一个矩阵组织 加州，戴维斯。204名成员被组织成6个项目，由8个共享项目提供支持 资源，并由高级领导领导，以便使用跨学科、转换性和变革性 旨在解决以下问题的研究：随着人口迅速老龄化，4000万美国人年龄以上 今天有65人活着，今年将有39万人死于癌症。在15年内，大约7400万人 这个年龄段的美国人将活下来，癌症死亡率将达到73万/年。目前的方法是通过 已开发的新癌症疗法的失败率令人失望；因此，改进了 翻译方法是必要的。将物理科学、生物医学 技术和功能成像，以开发新的治疗和交付方式以及 功能评估和增强的检测，以无毒的方式确定治疗是否有效。 有两个主要焦点用来解决这些问题： 1)减少癌症负担的差异 2)通过我们的患者来源的分子靶向治疗来治疗晚期癌症 异种移植计划(PDX)和犬类患者真正开发个性化药物。 这些项目中的每一个都使用多学科方法，结合不同项目的专业知识(分子 肿瘤学、比较肿瘤学、癌症治疗学、人口科学和健康差异、前列腺学 尿路上皮癌和生物医学技术)，利用加州大学戴维斯分校的专业知识(例如，医学院， 兽医学院，生物科学学院，生物医学技术系)，以及 与外部合作伙伴(杰克逊实验室、劳伦斯·利弗莫尔国家实验室、基金会 医学)。七个创新小组加强协作互动和提案，重点放在 将基本和技术成果转化为赠款和研究人员发起的试验(IIT)。除此之外， UCDCCC强大的临床试验计划使这些发现能够转化为患者的利益。这个 投资组合包括为第一、第二和第三阶段试验、COG和NCI肿瘤学比较试验提供资金的NCI奖 财团试验，以及强大的研究所投资组合。这些是由一群临床科学家实施的(其中11人 他们是在过去的资助期间招聘的)，他们的作用是翻译和临床的接口 研究。集水区(萨克拉门托县周围的13个县)受益于 活动，全市早期临床试验计划和UCDCCC癌症护理网络，通过 一个综合性癌症中心的资源和专业知识被带到贫困和农村 同时将患者留在他们的家乡社区。最后，在这个不断变化的癌症治疗的世界里 分娩模式，再加上越来越多的患者寻求帮助和越来越复杂的 在提供治疗的同时，我们正在建立一个强有力的癌症支持/心理肿瘤学计划。

PROJECT SUMMARY/ABSTRACT The UC Davis Comprehensive Cancer Center (UCDCCC), a consortium with Lawrence Livermore National Laboratories (LLNL), is a matrix organization under the aegis of the UC Davis Health System and University of California, Davis. Two hundred and four members are organized into six programs, supported by eight shared resources, and led by Senior Leadership in order to use transdisciplinary, translational, and transformative research to address the following problems: With a rapidly aging population, 40 million Americans over the age of 65 are alive today and 390,000 will die from cancer this year. In 15 years, approximately, 74 million Americans of this age will be alive and cancer mortality will be ~730,000/year. The present methods by which new cancer therapies have been developed have met with a disappointing failure rate; therefore, improved translational methods are needed. So too are integrated programs that combine physical sciences, biomedical technology, and functional imaging to develop new therapies and delivery modalities as well as methods for functional evaluation and enhanced detection to determine, in a non-toxic fashion, if therapies will work. Two main foci are used to address these problems: 1) Reducing disparities in the cancer burden 2) Tackling advanced cancer by adapting molecularly targeted therapy through our patient derived xenograft program (PDX) and canine patients to truly develop personalized medicine. Each of these uses a multi-disciplinary approach, combining expertise from across programs (Molecular Oncology, Comparative Oncology, Cancer Therapeutics, Population Sciences and Health Disparities, Prostate Urothelial Cancer, and Biomedical Technology), leveraging the UC Davis expertise (e.g., School of Medicine, School of Veterinary Medicine, College of Biological Sciences, Department of Biomedical Technology), and with external partners (the Jackson Laboratory, Lawrence Livermore National Laboratory, Foundation Medicine). Seven Innovation Groups enhance collaborative interactions and proposals with focus on translating basic and technological findings into grants and investigator-initiated trials (IITs). Beyond that, the UCDCCC’s robust clinical trials program enables these discoveries to be translated into patient benefits. The portfolio consist of NCI awards to fund Phase I, II, and III trials, COG and NCI Comparative Oncology Trials Consortium trials, and a strong portfolio of IITs. These are implemented by a cadre of clinical scientists (11 of whom were recruited in the past funding period) who function as the interface of translational and clinical research. The catchment area (13 counties surrounding Sacramento county) is benefited through, among other activities, a city-wide early phase clinical trials program and the UCDCCC Cancer Care Network, through which the resources and expertise of a comprehensive cancer center are brought to disadvantaged and rural areas while keeping patients in their home communities. Finally, in this world of ever-changing cancer care delivery models, combined with an increasing numbers of patients seeking help and increasing complexities of treatments available, we are building a robust cancer supportive/psycho oncology program.